Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma-Reference-Cited by-同舟云学术

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma

Published:2021-11-01 Issue:11 Volume:7 Page:1678
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kazandjian Dickran¹²,Hill Elizabeth¹,Dew Alexander¹³,Morrison Candis¹,Roswarski Joseph¹³,Korde Neha¹⁴,Emanuel Michael¹,Petrosyan Ani¹,Bhutani Manisha¹⁵,Calvo Katherine R.⁶,Dulau-Florea Alina⁶,Kwok Mary¹⁷,Lee Min-Jung⁸,Lee Sunmin⁸,Lindenberg Liza⁹,Mailankody Sham¹⁴,Manasanch Elisabet¹¹⁰,Maric Irina⁶,Mena Esther⁹,Patel Nisha⁶,Tageja Nishant¹¹¹,Trepel Jane B.⁸,Turkbey Baris⁹,Wang Hao-Wei¹²,Wang Weixin⁶,Yuan Constance¹²,Zhang Yong¹,Braylan Raul⁶,Choyke Peter⁹,Stetler-Stevenson Maryalice¹²,Steinberg Seth M.¹³,Figg William D.¹⁴,Roschewski Mark¹,Landgren Ola¹²

Affiliation:

1. Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

2. Multiple Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida

3. Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland

4. Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York

5. Levine Cancer Institute, Charlotte, North Carolina

6. Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland

7. Division of Hematology, University of Washington, Seattle

8. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

9. Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

10. Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, Texas

11. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

13. Biostatistics & Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

14. Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2783765/jamaoncology_kazandjian_2021_oi_210060_1636656347.71522.pdf

Reference27 articles.

1. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.;Landgren;Blood,2009

2. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma.;Landgren;JAMA Oncol,2019

3. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.;Kyle;N Engl J Med,2007

4. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.;Dispenzieri;Blood,2008

5. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.;Lakshman;Blood Cancer J,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Clonal Heterogeneity in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-01

2. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma;Cancer Consult;2023-11-18

3. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

4. Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering Myeloma;2023-08-31

5. Is aggressive treatment of smoldering myeloma the path to curing myeloma?;Blood Advances;2023-07-27